Corbus Pharmaceuticals Reports Q2 2025 Financials and Updates

Corbus Pharmaceuticals Holdings ( (CRBP) ) has released its Q2 earnings. Here is a breakdown of the information Corbus Pharmaceuticals Holdings presented to its investors.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity treatments, leveraging innovative scientific approaches to address serious illnesses. In its latest earnings report, Corbus Pharmaceuticals highlighted significant progress in its clinical programs, including the upcoming presentation of Phase 1/2 data for its Nectin-4 targeting ADC CRB-701 at ESMO 2025 and the advancement of its obesity drug CRB-913. The company reported a net loss of $17.7 million for the second quarter of 2025, with increased operating expenses primarily due to clinical development activities. Key developments include the FDA’s Fast Track designation for CRB-701 and the initiation of the multiple ascending dose portion of the CRB-913 Phase 1 trial. Looking ahead, Corbus Pharmaceuticals remains on track for data readouts across its clinical programs in the latter half of 2025, positioning itself for potential advancements in oncology and obesity treatment markets.